Protein kinase B (PKB) is known to mediate a number of biological responses to insulin and growth factors, its role in glucose uptake being one of the most extensively studied. In this work, we have employed a recently described allosteric inhibitor of PKB, Akti, to clarify the role of PKB in lipid metabolism in adipocytes-a subject that has received less attention. Pretreatment of primary rat and 3T3L1 adipocytes with Akti resulted in dose-dependent inhibition of PKB phosphorylation and activation in response to insulin, without affecting upstream insulin signaling [insulin receptor (IR), insulin receptor substrate (IRS)] or the insulininduced phosphoinositide 3-kinase (PI3K)-dependent activation of the ERK/p90 ribosomal kinase (RSK) pathway. PKB activity was required for the insulin-induced activation of phosphodiesterase 3B (PDE3B) and for the antilipolytic action of insulin. Moreover, inhibition of PKB activity resulted in a reduction in de novo lipid synthesis and in the ability of insulin to stimulate this process. The regulation of the rate-limiting lipogenic enzyme acetyl-CoA carboxylase (ACC) by insulin through dephosphorylation of S79, which is a target for AMP-activated protein kinase (AMPK), was dependent on the presence of active PKB. Finally, AMPK was shown to be phosphorylated by PKB on S485 in response to insulin, and this was associated with a reduction in AMPK activity. In summary, we propose that PKB is required for the positive effects of insulin on lipid storage and that regulation of PDE3B and AMPK by PKB is important for these effects.
THE SERINE/THREONINE protein kinase B (PKB/Akt) is a key target for signals that activate phosphoinositide 3-kinase (PI3K), such as insulin and growth factors. There is strong evidence, including results obtained from genetic mouse models, to support the idea that PKB mediates the effects of these stimuli on a multitude of cellular events such as glucose uptake, glycogen synthesis, gluconeogenesis, protein synthesis, and cell survival (12, 17) . The importance of PKB in the acute regulation of lipid metabolism by insulin is, however, less well characterized.
Perturbations in the ability of adipose tissue to adequately store triglycerides, and also in its endocrine function such as the production of adipokines, have been predicted to be an underlying cause of insulin resistance and type 2 diabetes. Lipid metabolism in adipocytes is controlled by the concerted actions of cAMP-elevating hormones and insulin. Insulin counteracts catecholamine-induced lipolysis (hydrolysis of triglycerides) mainly by inducing phosphorylation and activation of phosphodiesterase 3B (PDE3B) (13, 18, 19) . Activation of PDE3B leads to increased hydrolysis of cAMP, resulting in reduced activity of protein kinase A (PKA), which phosphorylates and activates hormone-sensitive lipase (HSL) as well as other target enzymes that carry out or regulate lipolysis (28, 40) . Overexpression and site-directed mutagenesis studies have suggested that PKB is the upstream kinase that phosphorylates PDE3B in response to insulin (2, 33) .
In addition to its antilipolytic action, insulin also promotes lipid storage by activating lipogenesis, i.e., de novo generation of lipids. The rate-limiting enzyme in fatty acid synthesis is acetyl-CoA carboxylase (ACC) (25) , which catalyzes the conversion of acetyl-CoA to the active fatty acid precursor malonyl-CoA. Malonyl-CoA at the same time limits fatty acid oxidation by inhibiting carnitine palmitoyltransferase I, which transports fatty acids into the mitochondrion (1) . One way in which insulin activates ACC is by inducing a net dephosphorylation of ACC at S79 (21, 56) , the site phosphorylated by AMP-activated protein kinase (AMPK) (15) . The mechanisms underlying insulin-induced dephosphorylation of this residue in ACC are not known, but overexpression of active PKB in adipocytes has been shown to increase lipogenesis (34, 56) . Moreover, AMPK in cardiac muscle has been shown to be phosphorylated by PKB in response to insulin, leading to an inhibition of phosphorylation of AMPK at T172 and therefore inhibition of its activity (29, 36) .
PKB is a member of the AGC (denoting PKA, PKG, PKC) family of kinases, and it is expressed as three isoforms in mammals: PKB␣, PKB␤, and PKB␥ (14) . Like many of the AGC kinases, PKB is activated through phosphorylation of a residue in the activation loop (T308 in PKB␣) by 3-phosphoinositide-dependent kinase (PDK)1 (4, 5) and by phosphorylation of a hydrophobic motif residue close to the COOH terminus (S473 in PKB␣) (4) . In the case of PKB, the kinase that brings about phosphorylation of the hydrophobic motif (PDK2) is the complex of mammalian target of rapamycin (mTOR) and rapamycin-insensitive companion of mTOR (RICTOR) (30) .
Previous studies addressing the role of PKB in lipid metabolism have mainly been based on the overexpression of constitutively active or dominant-negative versions of the kinase (2, 33, 34, 56) . Although useful in many regards, overexpression strategies are associated with certain pitfalls, which are discussed below. Pharmacological inhibition is a powerful method for the study of endogenous proteins and their role in acute hormone action. Moreover, pharmacological inhibition (or activation) is still by far the most common mechanism of action of drugs in clinical use, which demonstrates the importance of developing and characterizing such tools. Akti-1/2, hereafter referred to as Akti, is a recently described pharmacological inhibitor of PKB␣ and PKB␤ that inactivates PKB in vitro as well as in cells (8) . Akti has been found to have a 10-to 100-fold selective preference for PKB␣ and PKB␤ over 70 kinases in vitro, including PI3K and PDK1 (39) . Akti has also been shown to be capable of inhibiting insulin-induced phosphorylation and activation of PKB in cells, most likely by making it a worse substrate for its upstream kinases, without affecting other tested insulin-activated signaling pathways (24, 39) . Akti has been used to study the potential of PKB as a therapeutic target for anticancer drugs (8) and also to investigate the role of PKB in glucose uptake in L6 myotubes and 3T3L1 adipocytes (24, 23) and in the regulation of gluconeogenic gene expression (39) . In this study, we have used Akti in order to evaluate the role of PKB in the regulation of lipid metabolism in adipocytes.
MATERIALS AND METHODS

Materials.
Akti was a generous gift from Dario Alessi and Michael Keane (Univ. of Dundee, Dundee, UK), who synthesized it in-house (39) . Akti is also available commercially through Calbiochem, where it is termed Akt inhibitor VIII. 3T3L1 cells were obtained from the American Type Culture Collection; rats from Charles River Laboratories; DMEM, dexamethasone, wortmannin, and IBMX from Sigma; and insulin from Novo Nordisk (Copenhagen, Denmark). D-[6-3 H]-glucose (catalog no. TRK85) and protein G-Sepharose were purchased from GE Healthcare and [␥-32 P]ATP from PerkinElmer. Glycerokinase, glycerol-3-phosphate dehydrogenase, and NAD used for the glycerol determinations were from Roche, as were Complete protease inhibitor cocktail tablets. Precast Novex SDS polyacrylamide Bis-Tris gels, lauryl dodecyl sulfate (LDS) sample buffer, and fetal calf serum (FCS) were obtained from Invitrogen and phosphocellulose P81 paper from Whatman. The PDE3 inhibitor OPC3911 was a kind gift from Otsuka Pharmaceuticals. All peptides were synthesized by Dr. Graham Bloomberg (Univ. of Bristol, Bristol, UK). Enhanced chemiluminescence (ECL) Super Signal Reagent was purchased from Pierce.
The following antibodies were used for Western blotting: anti-PKB(pT308), anti-glycogen synthetase kinase (GSK)3(pS21/9), anti-HSL(pS563), anti-ACC, anti-ACC(pS79), anti-AMPK, anti-AMPK-(pT172), anti-AMPK(pS485), anti-ERK, anti-ERK(pT202/Y204) and anti-insulin receptor substrate (IRS)1 were all from Cell Signaling Technology (Beverly, MA), and anti-PKB(pS473), anti-GSK3, antiinsulin receptor (IR)(pY1162/1163) and anti-IRS1(pY612) were purchased from Biosource. Antibody to total PKB was a gift from Dario Alessi (Univ. of Dundee) and was raised against a peptide corresponding to residues 466-480 of rat PKB␣. Anti-HSL antibody was a gift from Cecilia Holm (Lund Univ.) and was raised against rat HSL. Anti-PDE3B antibodies were generated as described previously (49) . The following antibodies used for immunoprecipitation were all kindly provided by Dario Alessi and Kei Sakamoto (Univ. of Dundee): anti-PKB␣, raised against a fragment of human PKB␣ corresponding to residues 1-149; anti-mPKB␤ (used for immunoprecipitation of PKB␤ in 3T3L1 adipocytes), raised against a peptide corresponding to residues 455-469 of mouse PKB␤; anti-PKB␥, raised against a peptide corresponding to residues 116-128 of human PKB␥; and anti-p90 ribosomal kinase (RSK), raised against a peptide corresponding to residues 712-734 of human RSK2. The antibody used for immunoprecipitation of rat PKB␤ was generated in-house against a peptide corresponding to residues 455-469 of rat PKB␤. AMPK␣1 antibodies were generously provided by Grahame Hardie (Univ. of Dundee) and were raised against a peptide corresponding to residues 344-358 of rat AMPK␣1. The isoform specificity of the anti-PKB antibodies used for immunoprecipitation was validated in adipocyte lysates and with purified proteins, both by our group (data not shown) and by others (50) . Horseradish peroxidase-conjugated secondary antibodies were obtained from Biosource (anti-rabbit), Pierce (anti-sheep), and GE Healthcare (anti-mouse).
Culture and stimulation of 3T3L1 adipocytes. 3T3L1 fibroblasts were cultured at subconfluence in DMEM containing 10% FCS and 1% penicillin-streptomycin at 37°C and 95% air-5% CO 2. Two-day postconfluent cells were incubated for 72 h in DMEM supplemented with 0.5 mM IBMX, 10 g/ml insulin, and 1 M dexamethasone, and the cells were thereafter cultured in normal growth medium. Experiments were performed on days 8 -14 after the initiation of differentiation, at which time the differentiation rate was typically 80 -95%. Cells were stimulated as indicated in Figs. 1-4 and 6, rinsed briefly with PBS, and scraped in lysis buffer containing (in mM) 50 Tris ⅐ HCl, pH 7.5, 1 EGTA, 1 EDTA, 1 sodium orthovanadate, 10 sodium-␤-glycerophosphate, 50 sodium fluoride, 5 sodium pyrophosphate, and 1 dithiothreitol (DTT), with 1% (wt/vol) NP-40, 0.27 M sucrose, and Complete protease inhibitor cocktail (1 tablet/0.50 ml). Lysates were centrifuged at 13,000 g for 15 min at 4°C, and the infranatants were collected by punching a hole, with a needle, at the bottom of the tube. Total protein content of the lysates was determined by the method of Bradford.
For PDE3B measurements, cells were scraped and homogenized in lysis buffer without NP-40. PDE activity was measured either in a crude homogenate generated by centrifugation at 13,000 g for 15 min at 4°C or in membrane fractions generated by centrifugation of the homogenates at 35,000 g for 45 min at 4°C. Pellets were rehomogenized in the same buffer, and protein content was determined by the method of Bradford (11) .
Isolation and stimulation of primary rat adipocytes. Adipocytes were prepared from epididymal adipose tissue of 36-to 38-day-old male Sprague-Dawley rats (47) under a protocol approved by the ethical review committee at Lund University (approval no. M158-06). Adipocytes were suspended in Krebs-Ringer medium, 25 mM HEPES pH 7.4, 200 nM adenosine, 2 mM glucose, and 1% bovine serum albumin (BSA) (typically 2 ml of a 10% suspension), and stimulated as indicated in Figs. 1-6. To stop incubations, cells were washed in Krebs-Ringer medium without BSA and subsequently homogenized in 0.5-1 ml of homogenization buffer containing (in mM) 50 Tris ⅐ HCl pH 7.5, 1 EGTA, 1 EDTA, 1 sodium orthovanadate, 10 sodium-␤-glycerophosphate, 50 sodium fluoride, 5 sodium pyrophosphate, and 1 DTT, with 0.27 M sucrose and Complete protease inhibitor cocktail (1 tablet/0.50 ml). Homogenates were centrifuged for 5 min at 5,000 g, and the fat cake was removed. The remaining supernatant was supplemented with 1% (vol/vol) NP-40, left on ice to solubilize for 30 min, and centrifuged at 13,000 g for 10 min. Protein concentrations were determined by the method of Bradford.
PDE3B measurements were carried out either in detergent-free homogenates, prepared as above, or in membrane fractions generated by centrifugation of the homogenates at 35,000 g for 45 min at 4°C. Pellets were rehomogenized in the same buffer, and protein content was determined by the method of Bradford.
Western blot analysis. Total cell lysates or homogenates (5-30 g) were heated at 95°C for 2 min in LDS sample buffer, subjected to polyacrylamide gel electrophoresis on precast Novex gradient gels, and electrotransferred to nitrocellulose membranes. The membranes were blocked for 30 min in 50 mM Tris ⅐ HCl pH 7.6, 137 mM NaCl, and 0.1% (wt/vol) Tween 20 (TBS-T) containing 10% (wt/vol) skimmed milk. The membranes were then probed with 0.5-1 g/ml of the indicated antibodies in TBS-T containing 5% (wt/vol) skimmed milk or in 5% (wt/vol) BSA for 16 h at 4°C. Detection was performed with horseradish peroxidase-conjugated secondary antibodies and the ECL reagent (Pierce). Quantification of the bands was performed by digitizing the ECL films with a Fuji LAS 1000 charge-coupled device camera and analysis of the intensities with Image Gauge software (Fuji).
Kinase assays. Five to three hundred micrograms of cell lysate was incubated at 4°C for 1 h on a shaking platform with 1-5 g of anti-PKB, anti-RSK, or anti-AMPK antibodies (as described under Materials) conjugated to 5 l of protein G-Sepharose. The immunoprecipitates were washed twice with 0.5 ml of lysis buffer containing 0.5 M NaCl and 1 mM DTT and twice with 0.5 ml of 50 mM Tris ⅐ HCl pH 7.5, 0.1 mM EGTA, and 1 mM DTT (buffer A). Phosphotransferase activity toward peptide substrates was then measured in a total assay volume of 50 l containing 50 mM Tris ⅐ HCl pH 7.5, 0.1% (vol/vol) 2-mercaptoethanol, 10 mM MgCl 2, 0.1 mM EGTA, 0.1 mM [␥- 32 P]phosphate into the peptide substrate was determined by applying 40 l of the reaction mixture onto P81 phosphocellulose paper, followed by washing of the paper in 50 mM phosphoric acid and scintillation counting. One unit of activity was defined as that which catalyzed the incorporation of 1 nmol of 32 P into the substrate per minute. Assay of PDE3B. PDE3 activity was measured in 20 -30 g of adipocyte membrane fractions or total homogenates, as described previously (42) . The assay was performed at 30°C in a total volume of 300 l containing (in mM) 50 TES pH 7. Measurement of lipolysis and lipogenesis in 3T3L1 adipocytes. 3T3L1 adipocytes cultured in six-well plates were rinsed with PBS, preequilibrated in 800 l of Krebs-Ringer medium, 25 mM HEPES pH 7.4, 5 mM glucose, and 3% (wt/vol) BSA, and then treated with inhibitors and hormones as indicated in Fig. 4 . After 1 h of glycerol accumulation, the medium was removed and centrifuged, and 200 l was used for the enzymatic determination of glycerol content as described previously (53) .
For lipogenesis measurements, 3T3L1 adipocytes cultured in sixwell plates were rinsed with PBS, preequilibrated in 1 ml of KrebsRinger medium pH 7.4, 25 mM HEPES pH 7.4, 200 nM adenosine, 0.55 mM glucose, and 3.5% BSA, for 1 h and then treated with inhibitors and hormones, in the presence of D-[6-3 H]glucose, as indicated in Fig. 6 . The incorporation of D-[6-3 H]glucose into adipocyte triglycerides was determined by scintillation counting of the cells as described for rat adipocytes.
Statistical methods. Differences were analyzed with Student's t-test (2-tailed, paired) and were considered statistically significant when P Ͻ 0.05. Results are presented as means ϩ SE.
RESULTS
Akti is an efficient inhibitor of PKB in adipocytes.
To evaluate the efficiency of Akti in inhibiting PKB in different adipocyte cell types, primary rat and 3T3L1 adipocytes (of mouse origin) were pretreated with different doses of Akti or the PI3K inhibitor wortmannin and then stimulated with insulin. Increasing doses of either Akti or wortmannin prevented the ability of insulin to induce phosphorylation of PKB at the regulatory T308 and S473 sites in both cell types (Fig. 1, A and B) . In rat adipocytes, 7.5 M Akti was sufficient to inhibit 95% and 80% of the insulin-induced phosphorylation of T308 and S473, respectively. In 3T3L1 adipocytes, 3 M Akti abolished insulin-stimulated phosphorylation of PKB altogether. Aktimediated inhibition of PKB correlated with a similar prevention of insulin-induced phosphorylation of a well-established cellular PKB substrate, GSK3 (Fig. 1, A and B) , demonstrating that the inhibition of PKB phosphorylation does indeed translate into an inactivation of PKB in cells.
In vitro, Akti was reported to efficiently inhibit the ␣-and ␤-isoforms, with a slight preference for PKB␣ (with an IC 50 of 58 nM as opposed to 210 nM), whereas PKB␥ was poorly inhibited (IC 50 ϭ 2.1 M). It was also reported that Akti inhibited PKB␣ and PKB␤ activity, but not PKB␥, in a prostate tumor cell line (16) . Since pretreatment with Akti resulted in a near-complete ablation of the insulin-induced phosphorylation of PKB and since at least 3T3L1 adipocytes have been reported to express appreciable levels of PKB␥ (9), we were interested in analyzing the effect of Akti on the activities of individual PKB isoforms in adipocytes. To do this, we employed isoform-specific immunoprecipitation (see MATERIALS AND METHODS) of PKB␣, -␤, and -␥ in lysates from adipocytes treated with Akti and insulin and measured their activities toward a peptide substrate. As demonstrated in Fig. 1 , C and D, all three isoforms were detectable and activated by insulin in rat and 3T3L1 adipocytes. The activities of PKB␣ and PKB␤ were similarly inhibited in the two cell types, with a slightly higher efficiency toward the ␣-isoform. Submicromolar (0.1 M) Akti concentrations were sufficient to significantly reduce the insulin-induced activity of PKB␣ in 3T3L1 cells (Fig. 1D ) as well as in rat adipocytes (data not shown). Although significantly less sensitive to Akti, PKB␥ activation was also observed to be reduced in a dosedependent manner. The PKB␥ activity remaining at Akti concentrations of 10 M and 3 M, in rat and 3T3L1 adipocytes, respectively, did not significantly contribute to total PKB activity/phosphorylation, as demonstrated by the near to complete abrogation of insulin-stimulated phosphorylation of T308 and S473 (Fig. 1, A and B) . We also analyzed the sensitivity of glutathione S-transferase (GST)-PKB␥ expressed in HEK293 cells to Akti, and in this setting an Akti concentration of 10 M was sufficient to completely prevent phosphorylation and activation of PKB␥ in response to IGF-I (data not shown). In summary, Fig. 1 shows that Akti prevents total PKB phosphorylation/activity at 10 M and 3 M for rat and 3T3L1 adipocytes, respectively, and that concentrations of 1-3 M Akti are sufficient to inhibit PKB␣ and PKB␤ activities in both cell types.
Akti does not affect upstream insulin signaling or PI3K-dependent insulin-induced activation of ERK/RSK pathway. To rule out the possibility that Akti prevents the phosphorylation of PKB in cells by affecting upstream insulin signaling, we analyzed the phosphorylation of the IR at the activity-controlling sites Y1162 and Y1163 and IRS1 at Y612-one of the sites that mediate PI3K docking (20) . Increasing doses of Akti did not affect these tyrosine phosphorylations in rat ( Fig. 2A) or 3T3L1 (Fig. 2B) adipocytes . Surprisingly, wortmannin appeared to inhibit insulin-induced tyrosine phosphorylation of the IR in 3T3L1 adipocytes, although this was not the case in rat adipocytes and, furthermore, did not translate into reduced IRS phosphorylation in either cell type (Fig. 2B) . Moreover, Akti did not affect insulin-induced phosphorylation/activation of ERK1/2 and RSK in 3T3L1 adipocytes (Fig. 2C) , although this activation was sensitive to the PI3K inhibitor wortmannin, indicating that PI3K is not a target for Akti. Insulin-induced phosphorylation of ERK and activation of RSK2 appeared to be intact in the presence of as much as 30 M Akti (n ϭ 2 and 1, respectively; data not shown).
Collectively, the results presented in Figs. 1 and 2 demonstrate that Akti efficiently and specifically prevents the insulininduced phosphorylation and activation of PKB in rat and 3T3L1 adipocytes and is a useful tool in studying the role of PKB in lipid metabolism in these cells.
PKB is required for the antilipolytic action of insulin, through regulation of PDE3B.
That PKB has a role as an upstream kinase for PDE3B, the rate-limiting enzyme in insulin-induced antilipolysis, is widely accepted, but this has never been supported by pharmacological inhibition or genetic deletion of PKB (52) . As shown in Fig. 3 , acute inhibition of PKB by Akti resulted in significantly reduced activation of PDE3B in response to insulin in both adipocyte systems. Maximal inhibition occurred at 7.5 M and 3 M Akti in rat and 3T3L1 adipocytes, respectively, and these concentrations were as efficient as wortmannin in preventing PDE3B activation in response to insulin.
From studies employing PDE3B inhibitors or PDE3B-deficient mice (13, 19) , it is known that a major role of PDE3B in adipocytes is to mediate the antilipolytic effect of insulin. We therefore investigated the effect of Akti pretreatment on this biological response to insulin and monitored the phosphorylation status of HSL, which carries out catecholamine-induced lipolysis in adipocytes (51) . Stimulation of rat adipocytes with the ␤-adrenergic agonist isoproterenol resulted in increased phosphorylation of HSL at S563 (Fig. 4A) , which is a target for PKA and controls the A and B: cell lysates were analyzed by Western blot using phospho-specific antibodies as indicated. PKB immunoblots from 3-7 separate experiments were quantified and expressed as % of the insulin-stimulated sample and are presented as means ϩ SE. Representative blots are shown. GSK, glycogen synthase kinase. C and D: lysates were analyzed with regard to PKB activity by immunoprecipitation with isoform-specific antibodies and a peptide substrate. Activities were expressed as % of the insulin-stimulated sample and are presented as means ϩ SE of 2-5 separate experiments. Insulin-stimulated PKB activities in rat adipocytes ranged from 1.8 to 4.82 mU/mg (mean 2.47) for PKB␣, 1.0 to 4.61 mU/mg (mean 3.25) for PKB␤, and 0.14 to 0.42 mU/mg (mean 0.32) for PKB␥. Insulin-stimulated PKB activities in 3T3L1 cells ranged from 3.91 to 8.65 mU/mg (mean 5.71) for PKB␣, 0.92 to 1.51 mU/mg (mean 1.27) for PKB␤, and 2.17 to 5.73 mU/mg (mean 3.47) for PKB␥. Significant decrease from the sample stimulated with insulin in the absence of Akti: *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. lipolytic activity of HSL in vivo. The phosphorylation/ activation of HSL was reflected by an increased lipolytic rate (Fig. 4B) . In the absence of inhibitors, insulin treatment resulted in a complete reversal of HSL phosphorylation and a reduction of lipolysis back to the basal level. PKB inhibition, by increasing doses of Akti, did, however, potentiate the effects of isoproterenol on HSL phosphorylation and, most importantly, prevented the ability of insulin to counteract isoproterenol-induced HSL phosphorylation (Fig. 4A) and lipolysis (Fig. 4, B and C) . The PDE3 inhibitor OPC3911, in addition to wortmannin, also inhibited the antilipolytic effect of insulin. In 3T3L1 adipocytes, Akti similarly inhibited the antilipolytic action of insulin, although higher concentrations of Akti were required (Fig. 4, D-F) .
PKB is required for the ability of insulin to regulate ACC and for lipogenesis in adipocytes. Another important manner in which insulin promotes the storage of lipids, at least in rodents, is by stimulating de novo lipid formation. This is achieved mainly by activating ACC, the rate-limiting enzyme in fatty acid synthesis (25) . Insulin activates ACC, at least in part, by causing a net dephosphorylation of ACC at S79 (21, 56) . This site is known to be phosphorylated by AMPK, leading to inhibition of enzyme activity. As shown in Fig. 5A , insulin induced a significant (40%) decrease in the phosphorylation of ACC at S79. The dephosphorylation was dependent on the presence of active PKB, as demonstrated by the reversal of ACC S79 phosphorylation as a result of Akti pretreatment (Fig. 5A ). This reversal was observed at Akti concentrations down to 1 M (data not shown). These results would be consistent with AMPK being negatively regulated by insulin, through PKB phosphorylation, as has been demonstrated for AMPK in the heart (29, 36) . As shown in Fig. 5B , AMPK was indeed phosphorylated on S485, the suggested PKB site, in response to insulin. This was associated with a reduced phosphorylation of T172, and a significant (25%) decrease in activity of AMPK␣1, which is the major AMPK isoform in adipocytes (Fig.  5C ). PKB inhibition reversed the effects of insulin on AMPK phosphorylation (S485, T172) and activity.
Our results (Fig. 5) clearly show that active PKB is required for the ability of insulin to regulate the key lipogenic enzyme ACC, and that one mechanism involved in this regulation may be PKB-mediated inhibition of AMPK. We therefore next investigated the effect of PKB inhibition on lipogenesis, measured as the incorporation of [ 3 H]glucose into neutral lipids. In rat and 3T3L1 adipocytes, insulin induced two-and fourfold increase in the lipogenic rate, respectively (Fig. 6) . In rat adipocytes PKB inhibition resulted in a dose-dependent reduction of basal and insulininduced lipogenesis, with a complete abolishment of the (Fig. 6A) . In 3T3L1 adipocytes, inhibition of PKB led to greatly reduced insulin-induced lipogenesis, as well as a 50% reduction in the basal lipogenic rate (Fig. 6B) .
DISCUSSION
In this work, we show that Akti is a useful experimental tool to study the consequences of PKB inhibition in two adipocyte cell types, including primary rat adipocytes, which are physiological target cells for insulin ( Figs. 1 and 2) . Moreover, we provide definitive evidence that PKB is critical for the ability of insulin to activate PDE3B, and thereby antilipolysis (Figs. 3  and 4) . We also propose a novel mechanism for the regulation of ACC and lipogenesis, in which PKB carries out inhibitory phosphorylation of AMPK, leading to a net dephosphorylation, and hence activation, of ACC (Figs. 5 and 6). Our current view PDE3B activity was measured in detergent-free homogenates or in crude membrane fractions, and the results were expressed as % of the unstimulated sample. The results presented are means ϩ SE from 6 -8 independent experiments. Insulin-induced PDE3B activity in rat adipocytes ranged from 41.0 to 129.7 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 (membrane fractions) and from 6.2 to 20.9 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 (homogenates) and in 3T3L1 adipocytes from 34.5 to 39.1 pmol ⅐ min Ϫ1 ⅐ mg
Ϫ1
(membrane fractions) and from 4.9 to 20.9 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 (homogenates). Significant decrease from the sample stimulated with insulin in the absence of Akti: *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. of how insulin regulates lipid metabolism, and the role of PKB therein, is summarized in Fig. 7 .
Before the present study, because of the lack of specific PKB inhibitors, the role of PKB in lipid metabolism had only been investigated with overexpression (34, 56) . There are notable limitations to the use of these strategies: for example, overexpression of active PKB may lead to triggering of signaling pathways that are perhaps normally activated by other members of the AGC family of kinases; also, such overexpression does not determine the absolute requirement for PKB in a given process. Dominant-negative constructs may affect other signaling molecules besides PKB, such as AGC kinases that are also activated by PDK1 phosphorylation. Although the use of PKB-null mouse models is complicated by isoform redundancy, as well as the fact that compensatory mechanisms may arise as a consequence of permanent gene loss, these models still represent interesting systems for further study of the role of PKB in lipid metabolism. Our results show that Akti can potently inhibit PKB in adipocytes without affecting upstream signaling (IR, IRS) or other insulin-stimulated, PI3K-dependent signaling pathways (ERK/RSK). This is in line with recent data from Green et al. (24) , who reported similar findings in L6 myotubes. In that study, it was also demonstrated that Akti does not affect in vitro PI3K activity, the association between IRS1 and PI3K p85, or the insulin-induced generation of 3-phosphoinositides.
The specificity of Akti for different isoforms of PKB has mainly been studied in vitro, and it was shown to preferentially act on PKB␣ and PKB␤. Our immunoprecipitation kinase assays show that in adipocytes (Fig. 1, C and D) and in HEK293 cells expressing GST-PKB␥ (data not shown), Akti also prevents the activation of PKB␥, albeit at higher concentrations. The PKB␥ activity remaining at Akti concentrations of 10 M and 3 M in rat and 3T3L1 adipocytes, respectively, was not reflected in the analysis of total T308 and S473 phosphorylation (Fig. 1, A and B) , most likely suggesting that PKB␥ constitutes a relatively small portion of the total PKB protein in adipocytes. Although there have been reports of the existence of short forms of PKB␥ lacking the COOH-terminal regulatory S473 site (35) , the information now available in the database suggests that the two regulatory sites in PKB␥, and the sequences surrounding them, are completely conserved when comparing the rat, mouse (3T3L1), and human sequences. Phosphorylation of human GST-PKB␥ overexpressed in HEK293 cells was readily detected (data not shown), suggesting that the T308 and S473 phospho-specific antibodies do indeed recognize the phosphorylated PKB␥ epitopes. The relative abundance of the three isoforms is difficult to determine in detail because of the different efficiencies of the antibodies, as well as different specific activities of PKB isoforms toward the peptide substrate. We nevertheless addressed this issue by measuring the activity of PKB␣, PKB␤, and PKB␥, simultaneously, in lysates from insulin-stimulated adipocytes. PKB␥ only accounted for 5% of the total insulin-stimulated PKB activity in rat adipocytes and 16% in 3T3L1 adipocytes (data Fig. 5 . Effect of Akti on the regulation of acetyl-CoA carboxylase (ACC; A) and AMP-activated protein kinase (AMPK; B and C). Rat adipocytes were preincubated with or without Akti (1 h) or wortmannin (w; 100 nM, 20 min) as indicated and then simulated with insulin (Ins) for 10 min or left untreated (basal). Cell lysates were analyzed by Western blot using phospho-specific antibodies to ACC (A) and AMPK (B and C). ACC pS79 and AMPK pS485 immunoblots were quantified and expressed as % of the insulin-stimulated sample and are presented as means ϩ SE of 3-7 separate experiments. AMPK activity (C) was determined in AMPK␣1 immunoprecipitates with a peptide substrate. Significant difference between samples: *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001. not shown). These results suggest that the contribution of PKB␥ to total PKB activity/phosphorylation is relatively small in both cell types.
To understand the differences in the efficiency by which Akti acts on PKB isoforms in vitro and in vivo, it will be critical to fully characterize its molecular mechanism of action. Akti belongs to a series of compounds developed in 2005 by Lindsley et al. (38) , who showed that these inhibit PKB in a non-ATP-or substrate-competitive manner. This is one explanation as to why Akti displays a high degree of specificity for PKB over other kinases, most importantly members of the AGC family, which are highly homologous in their kinase domains (8, 39) . Instead, it was proposed that Akti acts allosterically by binding to a site that requires the pleckstrin homology (PH) domain of PKB, since antibodies to the PH domain or the hinge region were found to prevent the action of Akti, as did deletion of the PH domain (8) . Binding of the inhibitor has been postulated to promote a conformational change that renders the enzyme inactive but also prevents phosphorylation by upstream kinases. A recent study in fact identified a tryptophan residue (W80) in the PH domain of PKB, the mutation of which rendered the kinase insensitive to inhibition by Akti (24) . In L6 myotubes expressing the W80A mutant, but not the wild-type PKB, insulin-induced glucose uptake was maintained even in the presence of Akti. This demonstrates that Akti does indeed inhibit glucose uptake by specifically affecting PKB, and that W80 is critical for the action of Akti.
By employing pharmacological, selective inhibition of PKB, we have provided strong evidence that PKB is indeed an important upstream kinase for PDE3B (Fig. 3) , both in primary rat and 3T3L1 adipocytes. Our data are in line with previous reports demonstrating that PKB phosphorylates and thereby activates PDE3B in vitro (2, 33) . Moreover, several groups have also employed constitutively active and dominant negative versions of PKB to suggest that PKB acts upstream of PDE3B in 3T3L1 adipocytes, the promyeloid cell line FDCP2, and Xenopus oocytes (2, 7, 33) . It has also been shown that PKB and PDE3B coimmunoprecipitate and colocalize in macromolecular complexes, and that these complexes are important for the regulation of PDE3B by hormones (3) . In contrast to our data, Smith et al. (48) suggested that PKB activity was not critical for activation of PDE3B and for antilipolysis in adipocytes. These conclusions were made from experiments Results are presented as % of the basal value and are means ϩ SE from 4 -6 independent experiments. Significant decrease from the sample stimulated with insulin in the absence of Akti: **P Ͻ 0.01, ***P Ͻ 0.001. Fig. 7 . Role of PKB in lipid metabolism. This schematic overview summarizes our current understanding of the role of PKB in the regulation of lipogenesis and antilipolysis by insulin. Our data are consistent with PKB being required for the antilipolytic action of insulin, and with PKB being upstream of the antilipolytic enzyme PDE3B. Lipolysis is induced by the action of catecholamines [for example, isoprenaline (Iso)] on G protein-coupled receptors that activate adenylate cyclase (AC), resulting in elevated levels of cAMP and increased protein kinase A (PKA) and HSL activities. Insulin counteracts lipolysis by inducing the phosphorylation and activation of PDE3B by PKB, leading to hydrolysis of cAMP and attenuation of the lipolytic pathway. Moreover, we have shown that PKB is critical for lipogenesis and for the insulin-induced dephosphorylation/activation of the lipogenic enzyme ACC. One way in which PKB may regulate ACC is by direct phosphorylation of AMPK at S485, resulting in inhibition of phosphorylation of AMPK at T172 and of AMPK activity. This in turn leads to a net dephosphorylation and activation of ACC. Alternatively, since increased levels of cAMP and lipolysis have been shown to activate AMPK, PKB may inhibit AMPK indirectly by activating PDE3B, resulting in reduced cAMP levels. LKB1 is the main AMPK T172 kinase, at least in liver and muscle. using a myosin light chain kinase inhibitor, ML9, that also appeared to act on PKB. However, ML9 also efficiently inhibited other AGC kinases such as PKA and RSK. Especially in the case of lipolysis, results achieved with this tool are difficult to interpret, given the critical role of PKA in the regulation of lipolysis.
In Fig. 4 we demonstrate that the inability of insulin to normally activate PDE3B in the presence of Akti (see Fig. 3 ) is associated with an inhibition of the antilipolytic action of insulin in both cell types. However, the concentration of Akti required to prevent antilipolysis was greater in 3T3L1 adipocytes than in rat adipocytes, although 3T3L1 cells displayed a higher sensitivity to the inhibitor at the level of PKB, as judged by the results presented in Fig. 1 . It should be noted, however, that in the context of the glycerol accumulation experiment in 3T3L1 adipocytes, the sensitivity of PKB T308 phosphorylation to Akti was significantly lower (compare Fig. 4D with Fig.  1B ) and did in fact correlate with the inhibition of antilipolysis. The reasons for this apparent discrepancy in sensitivity are not clear; however, differences in the experimental conditions under which these two types of experiments were carried out (see MATERIALS AND METHODS) may have affected the efficiency of Akti.
Our data support the idea that PKB has an important role in the regulation of ACC and lipogenesis (Figs. 5 and 6 ). It is well established that insulin promotes the activation of ACC in several tissues and cell types, including liver and adipocytes; however, the mechanism underlying this effect of insulin has been less clear (26, 41, 54) . ACC is regulated by changes in its phosphorylation status, as well as allosterically by citrate (32) . In the 1980s, several papers reported the ability of insulin to increase phosphorylation of specific sites on ACC in adipocytes, as well as the identification of kinases capable of phosphorylating these in vitro (27, 32) . However, neither of the sites appeared to control ACC activity or its regulation by citrate (27) . Subsequently, Hardie and coworkers (15, 46) reported that phosphorylation of S79 in ACC by AMPK leads to its inactivation and also to a reduced sensitivity to citrate, and this is now believed to be the major regulatory mechanism for ACC. Our results showing that S79 phosphorylation is reduced in response to insulin (Fig. 5A ) are consistent with previous reports (21, 56) , and this most likely explains the activation of ACC by insulin. Moreover, our data with Akti support the notion that PKB has a critical role in this regulation (Fig. 5A) . Interestingly, recent work on the regulation of AMPK signaling in heart has identified a pathway by which insulin negatively regulates AMPK through phosphorylation by PKB (29, 36) . Our work is consistent with AMPK (S485) being a substrate for PKB in adipocytes (Fig. 5B) , and Akti inhibition of the PKB-mediated phosphorylation of AMPK was associated with increased AMPK activity (Fig. 5B) . Phosphopeptide mapping would have to be carried out in order to determine whether S485 is phosphorylated to a physiologically relevant level. Moreover, a nonphosphorylatable mutant of AMPK would be useful to determine the requirement for S485 in the negative regulation of AMPK by insulin and PKB in cells. Elevated cAMP levels in adipocytes are well known to stimulate AMPK activity (55) , and this was recently shown to be mediated by changes in AMP/ATP levels, as a result of reesterification of fatty acids released during lipolysis (22) . An alternative way in which PKB could inhibit AMPK in adipocytes is therefore via the activation of PDE3B, increased cAMP hydrolysis, and thus reduced lipolysis (Fig. 7) . This is, however, unlikely to account for the negative effects of insulin on AMPK in heart muscle, in which insulin-regulated isoforms of PDE do not appear to be expressed (31, 43) and lipolysis is not a significant metabolic route.
In our hands, activation of PKB in response to insulin resulted in a 25% reduction in AMPK activity. This is consistent with the results of previous studies showing that insulin stimulation reduced AMPK activity in a hepatoma cell line by 20 -30% (54) as well as inhibiting T172 phosphorylation of AMPK in 3T3L1 adipocytes (55) and in heart (36) . In contrast, another study, performed in rat adipocytes, reported that the activity of AMPK remained unchanged in response to insulin (45) . The reduction in AMPK activity that we observed could at least in part account for the effect of insulin on phosphorylation of S79 in ACC. In addition, it is possible that PKB is involved in the regulation of other sites in ACC, the phosphorylation of which may in turn prevent phosphorylation of S79, or that PKB regulates a phosphatase that can act on ACC S79. Insulin has indeed been shown to promote the association between ACC and an ACC phosphatase (37) .
Inhibition of PKB had profound effects on the lipogenic rate, leading to a reduction in basal and insulin-stimulated lipogenesis in both cell types (Fig. 6 ). Although pretreatment with Akti did slightly reduce basal PKB phosphorylation and activity ( Fig. 1) , basal phosphorylation of ACC remained unchanged in the presence of Akti (Fig. 5A) . It is possible that PKB-mediated regulation of other enzymes involved in lipogenesis could account for the reduction in basal lipogenesis, as well as in the insulin-induced lipogenesis observed in the presence of Akti. For example, ATP-citrate lyase, which catalyzes the formation of acetyl-CoA from citrate, has been reported to be a substrate for PKB; however, it is not clear whether PKB phosphorylation affects ATP-citrate lyase activity (10) . In rat adipocytes, the insulin-induced increase in lipogenesis was completely abolished in the presence of Akti. In Akti-treated 3T3L1 cells, insulin was still able to stimulate lipogenesis threefold, although the maximal lipogenic rate under these conditions was greatly reduced. This preserved stimulation could be accounted for by the remaining PKB␥ activity in these cells; alternatively, insulin may in a PKB-independent manner activate lipogenic enzymes other than ACC in 3T3L1 adipocytes.
